Terms: = Liver cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
196 results:
1. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract] [Full Text] [Related]
2. Nrf2 Regulates the Expression of
Siswanto FM; Handayani MDN; Firmasyah RD; Oguro A; Imaoka S
Curr Drug Metab; 2023; 24(9):667-681. PubMed ID: 37916628
[TBL] [Abstract] [Full Text] [Related]
3. Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro.
Ishikawa R; Saito K; Misawa T; Demizu Y; Saito Y
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371582
[TBL] [Abstract] [Full Text] [Related]
4. Combined Hepatocellular-Cholangiocarcinoma With Ductal Plate Malformation Pattern: A Case Report With Molecular Analysis.
Moon WS; Song JS; Yu HC; Kim KM; Ahn AR
Int J Surg Pathol; 2024 Feb; 32(1):160-164. PubMed ID: 37128663
[TBL] [Abstract] [Full Text] [Related]
5. Cross-Ancestry Genome-Wide Association Study Defines the Extended cyp2d6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Khor CC; Winter S; Sutiman N; Mürdter TE; Chen S; Lim JSL; Li Z; Li J; Sim KS; Ganchev B; Eccles D; Eccles B; Tapper W; Zgheib NK; Tfayli A; Ng RCH; Yap YS; Lim E; Wong M; Wong NS; Ang PCS; Dent R; Tremmel R; Klein K; Schaeffeler E; Zhou Y; Lauschke VM; Eichelbaum M; Schwab M; Brauch HB; Chowbay B; Schroth W
Clin Pharmacol Ther; 2023 Mar; 113(3):712-723. PubMed ID: 36629403
[TBL] [Abstract] [Full Text] [Related]
6. The roles of Cyp1a2 and cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Qin X; Xie C; Hakenjos JM; MacKenzie KR; Boyd SR; Barzi M; Bissig KD; Young DW; Li F
Eur J Pharm Sci; 2023 Feb; 181():106358. PubMed ID: 36513193
[TBL] [Abstract] [Full Text] [Related]
7. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.
Nio Y; Ishida H; Matsumoto N; Kusumoto S; Kubota Y; Tsunoda T; Sasaki Y; Fujita KI
BMC Pulm Med; 2022 Nov; 22(1):454. PubMed ID: 36451169
[TBL] [Abstract] [Full Text] [Related]
8. Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of cyp2d6 by dacomitinib.
Qiu X; Ren B; Lian Y; Fang L; Dong Z
J Oncol Pharm Pract; 2023 Jun; 29(4):1002-1005. PubMed ID: 36380705
[TBL] [Abstract] [Full Text] [Related]
9. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects.
Keller DN; Medwid SJ; Ross CD; Wigle TJ; Kim RB
Pharmacogenet Genomics; 2023 Jan; 33(1):10-18. PubMed ID: 36373739
[TBL] [Abstract] [Full Text] [Related]
10. Association of genetic polymorphisms of CYP3A4 and cyp2d6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract] [Full Text] [Related]
11. Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559.
Verma SK; Biswas A; Kumar M; Mishra A; Choudhury AD; Agrawal S; Sanap SN; Bisen AC; Sharma AK; Panda G; Bhatta RS
Xenobiotica; 2022 May; 52(5):476-487. PubMed ID: 35819259
[TBL] [Abstract] [Full Text] [Related]
12. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report.
Qiao F; Chen Q; Lu W; Fang N
Medicine (Baltimore); 2022 Jul; 101(27):e29629. PubMed ID: 35801736
[TBL] [Abstract] [Full Text] [Related]
13. Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing.
Ly RC; Shugg T; Ratcliff R; Osei W; Lynnes TC; Pratt VM; Schneider BP; Radovich M; Bray SM; Salisbury BA; Parikh B; Sahinalp SC; Numanagić I; Skaar TC
J Mol Diagn; 2022 Jun; 24(6):576-585. PubMed ID: 35452844
[TBL] [Abstract] [Full Text] [Related]
14. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
[TBL] [Abstract] [Full Text] [Related]
15. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
[TBL] [Abstract] [Full Text] [Related]
16. Biological Activity and Stability of Aeruginosamides from Cyanobacteria.
Cegłowska M; Kwiecień P; Szubert K; Brzuzan P; Florczyk M; Edwards C; Kosakowska A; Mazur-Marzec H
Mar Drugs; 2022 Jan; 20(2):. PubMed ID: 35200623
[TBL] [Abstract] [Full Text] [Related]
17. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
Piscitelli J; Chen J; LaBadie RR; Salageanu J; Chung CH; Tan W
Clin Drug Investig; 2022 Mar; 42(3):221-235. PubMed ID: 35195881
[TBL] [Abstract] [Full Text] [Related]
18. Transgenic HepaRG cells expressing cyp2d6 as an improved model of primary human hepatocytes.
Okuyama S; Mine A; Nakamura T; Ohasi Y; Seto M; Tada M
Pharmacol Res Perspect; 2022 Apr; 10(2):e00939. PubMed ID: 35174659
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different cyp2d6 genotypes: A propensity-score matched cohort study.
Zhou W; Jiang Y; Xu Y; Wang Y; Ma X; Zhou L; Lin Y; Wang Y; Wu Z; Li M; Yin W; Lu J
Int J Cancer; 2022 May; 150(10):1664-1676. PubMed ID: 34957551
[TBL] [Abstract] [Full Text] [Related]
20. Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives.
Cura Y; Pérez Ramírez C; Sánchez Martín A; Martínez Martínez F; Calleja Hernández MÁ; Ramírez Tortosa MDC; Jiménez Morales A
Mutat Res Rev Mutat Res; 2021; 788():108391. PubMed ID: 34893156
[TBL] [Abstract] [Full Text] [Related]
[Next]
